Clinical trial Recruiting at 2 sites Observational Ages 6 Months to 22

Observational study on chronic kidney disease in children

Official title: Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)

Run by Johns Hopkins Bloomberg School of Public Health · NCT00327860 · Data updated 2026-11-12

This study looks at how chronic kidney disease affects children's health and growth to see what factors might lead to kidney problems as they grow up.

Quick facts

Study typeObservational
Ages6 Months to 22 Years
SexAll
Enrollment1300 (estimated)
SponsorJohns Hopkins Bloomberg School of Public Health
Academic / other
Drugs / interventionstrastuzumab, chemotherapy
Locations2 sites (Kansas City, Missouri and 1 other locations)
StatusRecruiting
StartedOctober 2003
Main results expectedJuly 2028
Study endsJuly 2028
Registry record updatedApril 17, 2026
Trial IDNCT00327860 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are children aged 1 to 22 years with chronic kidney disease who are regularly seen by a pediatric nephrologist.

Probably not a fit

Patients with solid organ transplants, recent cancer treatment, or HIV may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Chronic Kidney Disease in Children Prospective Cohort Study (CKiD) is an observational study aimed at understanding the risk factors for decline in kidney function among children with chronic kidney disease (CKD). Conducted by a collaboration of prominent institutions, the study collects data on various health outcomes, including cardiovascular health, neurocognitive function, and growth failure. It involves multiple cohorts of children and young adults, with a focus on how CKD impacts their overall health and transition to adult care. The study has been ongoing since 2003 and aims to provide insights that could improve management and outcomes for affected children.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management strategies for children with chronic kidney disease, potentially enhancing their long-term health outcomes.

How similar studies have gone: Other studies focusing on chronic kidney disease in children have shown promising results, indicating that this approach is supported by previous research.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age between 1 and 16 years (before 17th birthday) for Cohorts 1 and 2; age between 6 months and 16 years (before 17th birthday) for Cohort 3; age between 16 to 22 years (before 23rd birthday) for Cohort 4
* Estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min\|1.73m2 for Cohort 1 OR an estimated GFR between 45 and 90 ml/min\|1.73m2 based on the updated Schwartz formula for Cohort 2; an estimated GFR ≤60 based on the CKiD Under 25 estimating equation (U25eGFR) OR KRT experience (dialysis or transplant) for Cohort 4
* Willingness and ability to provide informed consent and assent
* For Cohort 3, children with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.

Exclusion Criteria:

* Solid organ (other than kidney), bone marrow or stem cell transplantation
* Cancer diagnosis and receiving treatment or within 12 months post completion of treatment
* Ongoing monitoring for cardiotoxic effects of prior chemotherapy or targeted cancer therapies (e.g., anthracyclines, trastuzumab)
* HIV infection with detectable viral load despite current antiretroviral therapy
* Current pregnancy or pregnancy within past twelve months
* Inability to complete major data collection procedures
* Not fluent in English or Spanish
* Plans to move out of area of any participating CKiD site (families can be transferred to another CKiD site if the family moves)
* Existing moderate to severe congenital structural heart disease
* Genetic syndromes involving the central nervous system (e.g., Downs syndrome)
* History of severe to profound intellectual disability (i.e., Intelligence Quotient (IQ)\<40, significant impairment in adaptive function and/or inability to independently execute self-care skills)
* For cohort 3, children who are expected to receive renal replacement therapy within 6 months of date of enrollment will not be recruited

Where it's running

  • Children's Mercy Kansas City
    Kansas City, Missouri, United States
    Recruiting
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania, United States
    Recruiting

Study contacts

  • Principal investigator: Susan Furth, MD, PhD — Children's Hospital of Philadelphia
  • Study coordinator: Susan Furth, MD, PhD
  • Email: FurthS@email.chop.edu
  • Phone: 215-590-2449

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.